Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age25-70
SponsorNicolai Jacob Wewer Albrechtsen

About this trial

The aim of the study is to develop a non-invasive method for quantifying cerebral glucose metabolism by PET scans in humans. This method will be used in subsequent studies, where the effect of the pancreatic hormone glucagon on cerebral glucose metabolism will be studied.

The golden standard for quantifying cerebral glucose metabolism by PET scans is based on arterial blood sampling, which complicates research setup. This study will investigate if image derived measurements instead of arterial blood samples can be used to quantify cerebral glucose metabolism.

We will compare the calculations of cerebral glucose metabolism based on arterial blood samples and image derived measurements and hopefully these will correlate.

Healthy participants will be included, and each participant will participate in one study day, which includes intravenous administration of radioactively labelled glucose (18-FDG), arterial blood sampling and PET scans.

Eligibility criteria

Qualifiers

Capable of understanding the participant information and signing the consent form

Between 25 and 70 years of age

Body mass index <= 25 kg/m²

Disqualifiers

Enrolment in other research project that might interfere with the study

Diabetes diagnosis

Pregnancy or breastfeeding

Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol

Trial design

Treatments tested in this trial

  • PET with 18-FDG

Treatment groups

6 Participants
are divided into 1 treatment group

Sponsors and collaborators

Nicolai Jacob Wewer Albrechtsen

Lead sponsor

University of Copenhagen

Sponsor institution

University Hospital Bispebjerg and Frederiksberg

Collaborator